Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.72 |
| ▸ | PPARA | Q07869 | 3/20 | 0.72 |
| ▸ | PPARD | Q03181 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157216 | 1.00 | PPARG (0.72) | PPARGPPARAPPARD | |
| SCHEMBL6612891 | 0.92 | PPARG (0.69) | PPARGPPARAPPARD | |
| SCHEMBL6611075 | 0.88 | PPARG (0.70) | PPARGPPARAPPARD | |
| SCHEMBL6612058 | 0.87 | PPARG (0.69) | PPARGPPARAPPARD | |
| SCHEMBL6608996 | 0.87 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL6608390 | 0.86 | PPARG (0.67) | PPARGPPARAPPARD | |
| SCHEMBL6611004 | 0.86 | PPARG (0.67) | PPARGPPARAPPARD | |
| SCHEMBL5971527 | 0.86 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL6614464 | 0.85 | PPARG (0.66) | PPARGPPARAPPARD | |
| SCHEMBL6614266 | 0.85 | PPARG (0.66) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002033121-A2 | TEST FOR THE DIAGNOSIS OF DIABETES AND COMPOUNDS FOR THE TREATMENT THEREOF | GLAXO GROUP LIMITED (GB) | 2002-04-25 | — | — | WO | claimed |
| US-20090298745-A1 | Treatment of Diabetes with Glycogen Phosphorylase Inhibitors | PROSIDION LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| WO-2006059163-A1 | TREATMENT OF DIABETES WITH GLYCOGEN PHOSPHORYLASE INHIBITORS | PROSIDION LIMITED (GB) | 2006-06-08 | — | — | WO | disclosed |
| EP-1663200-A2 | COMBINATION THERAPY FOR GLYCAEMIC CONTROL | Prosidion Limited (GB) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005020983-A2 | COMBINATION THERAPY FOR GLYCAEMIC CONTROL | PROSIDION LTD. (GB) | 2005-03-10 | — | — | WO | disclosed |
| WO-2001028539-A2 | AGENT FOR TREATING CEPHALIC PAIN | GLAXO GROUP LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298745-A1 | Treatment of Diabetes with Glycogen Phosphorylase Inhibitors | PYGL, PYGM, G6PC1 | PPARG 1970/4885PPARA 2125/4885PPARD 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.